Back to first-pass browser

First-pass extracted concept

AAV-based RPGR gene therapy

Candidate: concept label1 source documents6 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This is the reviewed therapeutic approach of using AAV vectors to deliver RPGR for treatment of RPGR-associated XLRP. The review evaluates its clinical efficacy and safety across controlled trials.

Source 1DOIPubMed

What problem it solves

It is intended as a gene therapy approach for a severe hereditary retinal dystrophy that lacks curative treatments.

Source 1DOIPubMed

What it does not solve

The review indicates it did not significantly improve best-corrected visual acuity or LLVA at the higher 15-letter threshold in the pooled short-term analysis, and safety risks remain.

Source 1DOIPubMed

Alternatives

The abstract does not name alternative therapeutic modalities; it frames AAV-mediated RPGR gene therapy as a novel approach in a disease with no curative treatments.

Source 1DOIPubMed

Evidence Snippets

This study aimed to conduct a systematic review and meta-analysis to synthesize clinical evidence on adeno-associated viral (AAV)-based RPGR gene therapy for X-linked retinitis pigmentosa (XLRP).
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1clinical efficacymixed2026Source 1DOIPubMed

AAV-based RPGR gene therapy did not show significant pooled improvement in best-corrected visual acuity or in low-luminance visual acuity at the 15-letter threshold.

Claim 2clinical efficacysupports2026Source 1DOIPubMed

AAV-based RPGR gene therapy significantly improved low-luminance visual acuity by at least 10 ETDRS letters at 6 months in pooled controlled clinical evidence for RPGR-associated XLRP.

Claim 3clinical efficacysupports2026Source 1DOIPubMed

AAV-based RPGR gene therapy significantly improved retinal sensitivity at 6 months and 12 months in pooled controlled clinical evidence for RPGR-associated XLRP.

Claim 4evaluation timingsupports2026Source 1DOIPubMed

The review identifies 6 months as a critical evaluation time point for assessing short-term efficacy of AAV-based RPGR gene therapy in XLRP.

Claim 5safety risksupports2026Source 1DOIPubMed

AAV-based RPGR gene therapy significantly increased ocular treatment-emergent adverse event risk in pooled controlled clinical evidence for RPGR-associated XLRP.

Claim 6safety signalsupports2026Source 1DOIPubMed

Common ocular adverse events reported with AAV-based RPGR gene therapy included anterior chamber inflammation and intraocular inflammation, and serious adverse events trended higher.